Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATRN-119

Small molecule · Inhibitor of ataxia telangiectasia and Rad3 related kinase (ATR) · developed by Aprea Therapeutics

Phase 1/2 Most advanced trial (none active)

APRE Developer

1 Registered trials

What is ATRN-119?

ATRN-119 is an orally bioavailable small molecule that selectively binds and inhibits the DNA damage response kinase ATR. By blocking ATR signaling and downstream CHK1 phosphorylation, it disrupts DNA damage checkpoint activation and DNA repair, leading to tumor cell apoptosis. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: ataxia telangiectasia and Rad3 related kinase (ATR)
Mechanism: Inhibitor of ataxia telangiectasia and Rad3 related kinase (ATR)
Pathways: DNA damage response, CHK1 phosphorylation, DNA damage checkpoint activation, DNA repair, apoptosis
Therapy area: Oncology
Developer: Aprea Therapeutics (APRE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04905914	Phase 1/2	Advanced Solid Tumor	Completed	APRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on ATR

Ceralasertib Phase 1 IMP9064 Investigational

More from Aprea Therapeutics

APR-1051 Phase 1 APR-548 Phase 1 Eprenetapopt Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the APRE page.

Follow APRE, the company behind ATRN-119

See APRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APRE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z